Evidence mapPaperPMID 42483180Full record

ReviewFrontiers in immunology2026

IL-6 as a central driver of immune evasion in PDAC: from IDO-mediated tolerance to multi-pathway immunosuppression.

Joyce Wang, Jolene Su Yi Tan, Vishal G Shelat, Jackwee Lim

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joyce WangSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Jolene Su Yi TanDepartment of Neurology, Tan Tock Seng Hospital, Singapore, Singapore.
Vishal G ShelatDepartment of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore.
Jackwee LimSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers and is characterised by an immunologically "cold" microenvironment that limits responses to immunotherapy. This review focuses on interleukin-6 (IL-6), produced by stromal and immune cells as well as PDAC cells, as a central driver of immune evasion via JAK-STAT3 signalling. We outline how SOCS3 silencing in tumour cells inverts the IL-6-IDO relationship seen in dendritic cells, generating an autocrine IDO-Kyn-AhR-IL-6-STAT3 feedforward loop. We further describe IL-6-mediated stabilisation of PD-L1, sustained PD-1 expression on CD8

Indexed as

Carcinoma, Pancreatic DuctalInterleukin-6Pancreatic NeoplasmsSTAT3 Transcription FactorTumor EscapeAntigens, CDB7-H1 Antigenbeta-D-Galactoside alpha 2-6-SialyltransferaseImmune ToleranceIndoleamine-Pyrrole 2,3,-DioxygenaseSuppressor of Cytokine Signaling 3 ProteinAntigens, CDB7-H1 Antigenbeta-D-Galactoside alpha 2-6-SialyltransferaseCD274 protein, humanIDO1 protein, humanIL6 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseInterleukin-6SOCS3 protein, humanST6GAL1 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 Proteinimmune checkpointsimmune evasionJAK-STAT-3 signallingpancreatic ductal adenocarcinomaregulatory T cellstargeted therapytumour microenvironment

Identifiers

PMID42483180
PMCPMC13384895

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.